February 1, 2017
Takeda Pharmaceutical said on January 31 that it has obtained exclusive rights in Japan to develop and commercialize the cancer drug candidate cabozantinib of US biotechnology firm Exelixis for all potential indications. Cabozantinib is sold under the trade name of...read more